Tamarind trypsin inhibitor in chitosan–Whey protein nanoparticles reduces fasting blood glucose levels without compromising Insulinemia: a preclinical study

Página do item simplificado Estatísticas
dc.contributor.authorMorais, Ana Heloneida de Araújo
dc.contributor.authorMatias, Lidia Leonize Rodrigues
dc.contributor.authorCosta, Rafael Oliveira de Araújo
dc.contributor.authorPassos, Thais Souza
dc.contributor.authorQueiroz, Jaluza Luana Cravalho de
dc.contributor.authorSerquiz, Alexandre Coelho
dc.contributor.authorMaciel, Bruna Leal Lima
dc.contributor.authorSantos, Pedro Paulo de Andrade
dc.contributor.authorCamillo, Cristina da Silva
dc.contributor.authorGonçalves, Catarina
dc.contributor.authorAmado, Izabel Rodriguez
dc.contributor.authorPastrana, Lorenzo
dc.contributor.authorIDhttps://orcid.org/0000-0002-6460-911Xpt_BR
dc.date.accessioned2023-09-06T19:57:20Z
dc.date.available2023-09-06T19:57:20Z
dc.date.issued2019
dc.description.resumoIn vivo studies show the benefits of the trypsin inhibitor isolated from tamarind (Tamarindusindica L.) (TTI) seeds in satiety and obesity. In the present study, TTI nanoencapsulation (ECW) was performed to potentialize the effect of TTI and allow a controlled release in the stomach. The impact on glycemia, insulin, and lipid profile was evaluated in Wistar rats overfed with a high glycemic index diet (HGLI). Characterization of the nanoparticles and in vitro stability in simulated gastrointestinal conditions, monitored by antitrypsin activity and HPLC, was performed. ECW and empty nanoparticles (CW) were administered by gavage, using 12.5 and 10.0 mg/kg, respectively. Both nanoformulations presented a spherical shape and smooth surface, with an average diameter of 117.4 nm (24.1) for ECW and 123.9 nm (11.3) for CW. ECW maintained the antitrypsin activity (95.5%) in the gastric phase, while TTI was completely hydrolyzed. In Wistar rats, the nanoformulations significantly reduced glycemia and HOMA IR, and ECW increased HDL-c compared to CW (p < 0.05).Pancreas histopathology of animals treated with ECW suggested an onset of tissue repair. Thenanoencapsulation provided TTI protection, gradual release in the desired condition, and improvement of biochemical parameters related to carbohydrate metabolism disorders,without compromising insulinemiapt_BR
dc.identifier.citationMATIAS, Lídia L. R. et al. Tamarind trypsin inhibitor in chitosan–whey protein nanoparticles reduces fasting blood glucose levels without compromising insulinemia: a preclinical study. Nutrients, v. 11, n. 11, p. 2770, 2019.Disponível em: https://www.mdpi.com/2072-6643/11/11/2770. Acesso em: 7 jul. 2023.pt_BR
dc.identifier.doi10.3390/nu11112770
dc.identifier.urihttps://repositorio.ufrn.br/handle/123456789/54725
dc.languageenpt_BR
dc.publisherNutrientspt_BR
dc.subjectTamarindusindica L.pt_BR
dc.subjectencapsulationpt_BR
dc.subjectoverfeedingpt_BR
dc.subjectdigestionpt_BR
dc.subjectfasting glucosept_BR
dc.subjectinsulinpt_BR
dc.titleTamarind trypsin inhibitor in chitosan–Whey protein nanoparticles reduces fasting blood glucose levels without compromising Insulinemia: a preclinical studypt_BR
dc.typearticlept_BR

Arquivos

Pacote Original

Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
TamarindTrypsin_Matias_2019.pdf
Tamanho:
6.03 MB
Formato:
Adobe Portable Document Format
Nenhuma Miniatura disponível
Baixar

Licença do Pacote

Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
license.txt
Tamanho:
1.45 KB
Formato:
Item-specific license agreed upon to submission
Nenhuma Miniatura disponível
Baixar

Coleções

CCS - DNUT - Artigos publicados em periódicos
Repositório Institucional - UFRN Campus Universitário Lagoa NovaCEP 59078-970 Caixa postal 1524 Natal/RN - BrasilUniversidade Federal do Rio Grande do Norte© Copyright 2025. Todos os direitos reservados.
Contato+55 (84) 3342-2260 - R232Setor de Repositórios Digitaisrepositorio@bczm.ufrn.br
DSpaceIBICT
OasisBR
LAReferencia
Customizado pela CAT - BCZM